Full breakdown of the pathway, the regulatory citations, and the documented medical-need criteria RxPepsDirect providers use is on our compounded tirzepatide legality page
Semaglutide may be unsuitable or require additional caution in patients who: are pregnant, breastfeeding or trying to conceive have a history of pancreatitis have severe gastrointestinal disease have delayed stomach emptying have significant kidney or liver impairment use insulin or medicines that can cause hypoglycaemia have diabetic retinopathy have an active or previous eating disorder have experienced a serious allergic reaction to semaglutide already use another GLP-1 or GIP/GLP-1 medicine are due to undergo surgery, sedation or general anaesthesia These factors are not all automatic exclusions
Patients should be counseled about distinguishing between expected medication side effects and symptoms requiring medical attention
The SHAPE study: real-world evidence The SHAPE study, published in 2025, examined real-world weight loss in patients with overweight or obesity who did not have type 2 diabetes
If some of these side effects are left untreated and become severe, serious health consequences can occur, including renal failure and even death